학술논문
Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial
Document Type
Article
Author
Pieber, Thomas R; Bode, Bruce; Mertens, Ann; Cho, Young Min; Christiansen, Erik; Hertz, Christin L; Wallenstein, Signe O R; Buse, John B; Akın, S; Aladağ, N; Arif, A A; Aronne, L J; Aronoff, S; Ataoglu, E; Baik, S H; Bays, H; Beckett, P L; Berker, D; Bilz, S; Bode, B; Braun, E W; Buse, J B; Canani, L H S; Cho, Y M; Chung, C H; Colin, I; Condit, J; Cooper, J; Delgado, B; Eagerton, D C; El Ebrashy, I N; El Hefnawy, M H M F; Eliaschewitz, F G; Finneran, M P; Fischli, S; Fließer-Görzer, E; Geohas, J; Godbole, N A; Golay, A; Gorban de Lapertosa, S; Gross, J L; Gulseth, H L; Helland, F; Høivik, H O; Issa, C; Kang, E S; Keller, C; Khalil, S H A; Kim, N H; Kim, I J; Klaff, L J; Laimer, M; LaRocque, J C; Lederman, S N; Lee, K-W; Litchfield, W R; Manning, M B; Mertens, A; Morawski, E J; Murray, A V; Nicol, P R; O'Connor, T M; Oğuz, A; Ong, S; Özdemir, A; Palace, E M; Palchick, B A; Pereles-Ortiz, J; Pieber, T; Prager, R; Preumont, V; Riffer, E; Rista, L; Rudofsky, G; Sarı, R; Scheen, A; Schultes, B; Seo, J A; Shelbaya, S A; Sivalingam, K; Sorli, C H; Stäuble, S; Streja, D A; T'Sjoen, G; Tetiker, T; Van Gaal, L; Vercammen, C; Warren, M L; Weinstein, D L; Weiss, D; White, A; Winnie, M; Wium, C; Yavuz, D
Source
The Lancet Diabetes & Endocrinology; July 2019, Vol. 7 Issue: 7 p528-539, 12p
Subject
Language
ISSN
22138587; 22138595
Abstract
Oral semaglutide is the first oral formulation of a glucagon-like peptide-1 (GLP-1) receptor agonist developed for the treatment of type 2 diabetes. We aimed to compare the efficacy and safety of flexible dose adjustments of oral semaglutide with sitagliptin 100 mg.